Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 272-056-6 | CAS number: 68672-66-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 January 2018 to 20 March 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- (Z)-α-[[2-(tert-butoxy)-1,1-dimethyl-2-oxoethoxy]imino]-2-(tritylamino)thiazol-4-acetic acid
- EC Number:
- 272-056-6
- EC Name:
- (Z)-α-[[2-(tert-butoxy)-1,1-dimethyl-2-oxoethoxy]imino]-2-(tritylamino)thiazol-4-acetic acid
- Cas Number:
- 68672-66-2
- Molecular formula:
- C32H33N3O5S
- IUPAC Name:
- (2Z)-2-({[1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl]oxy}imino)-2-{2-[(triphenylmethyl)amino]-1,3-thiazol-4-yl}acetic acid
- Test material form:
- solid: particulate/powder
- Details on test material:
- white powder
Constituent 1
- Specific details on test material used for the study:
- Batch number: G317115
Expiry: 04 March 2021 (re-test)
Appearance: White to off-white powder
Storage conditions:
15 to 25°C, desiccated, protected from light
Purity: 96.29 % w/w
Weighing factor for formulation: 1.04g contains 1.000g, as free side chain
Date received: 01 December 2017
Method
Species / strain
- Species / strain / cell type:
- other: human lymphocytes
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix
- Test concentrations with justification for top dose:
- The following test item concentrations were selected for metaphase analysis:
In the absence of S9 mix, 3-hour treatment (additional test): 20, 50 and 70 µg/mL.
In the presence of S9 mix, 3-hour treatment: 20, 30 and 40 µg/mL.
In the absence of S9 mix, 21-hour treatment (additional test): 10, 20 and 27.5 µg/mL.
The final concentrations of 1132 Side Chain to which cells were exposed initially are given below. Preliminary toxicity test: 3.91, 7.81, 15.63, 31.25, 62.5, 125, 250, 500, 1000 and 2000 µg/mL
Main tests: -S9 mix (3 hours) 10, 20, 30, 40, 50, 60 and 70 µg/mL
-S9 mix (3 hours) 20, 30, 40, 50, 60, 70 and 80 µg/mL
+S9 mix (3 hours) 5, 10, 20, 30, 40, 50 and 60 µg/mL
-S9 mix (21 hours) 5, 10, 15, 20, 25, 30 and 35 µg/mL
-S9 mix (21 hours) additional) 10, 15, 20, 25, 27.5, 30, 32.5 and 35 µg/mL - Vehicle / solvent:
- DMSO was used as the vehicle control.
Controls
- Untreated negative controls:
- yes
- Remarks:
- VEHICLE CONTROL
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- yes
- Remarks:
- VEHICLE CONTROL
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: In preliminary and main tests the cells were treated for 3 and 21 hours in the absence of S9 mix and for 3 hours in the presence of S9 mix. In the additional main test the cells were treated for 3 and 21 hours in the absence of S9 mix.
- Expression time (cells in growth medium): Cultures were grown for 48 hours before treatment
-Harvesting and Fixation
Two hours before the cells were harvested, mitotic activity was arrested by addition of Colcemid® to each culture at a final concentration of 0.1 µg/mL. After 2 hours incubation, each cell suspension was transferred to a centrifuge tube and centrifuged for 5 minutes at 500g. The supernatant was removed and the cell pellets were treated with a hypotonic solution (0.075M KCl) for a 10 minute period at between 34 to 39°C. The suspensions were centrifuged at 500g for 5 minutes, supernatant removed and the cell pellets fixed by addition of ice-cold fixative (methanol:glacial acetic acid (3:1 v/v)). Following further centrifugation the supernatant was removed and replaced with fixative; this was repeated twice until the fixative was clear.
SPINDLE INHIBITOR (cytogenetic assays): Colcemid®
METHODS OF SLIDE PREPARATION AND STAINING TECHNIQUE USED: Slide Preparation
The fixed pellets were re-suspended, then centrifuged at 500g for 5 minutes and re-suspended in a small volume of fixative. A few drops of the cell suspensions were dropped onto precleaned microscope slides and allowed to air dry.One slide was prepared per culture. The slides were then stained in 10% Giemsa, prepared in buffered water (pH 6.8). After rinsing in buffered water the slides were left to air-dry and mounted in DPX. The remainder of the cell suspensions in fixative were stored at 2 to 8°C until slide analysis was completed.
NUMBER OF CELLS EVALUATED: The prepared slides were examined by light microscopy and the incidence of mitotic cells per 1000 cells assessed.
NUMBER OF METAPHASE SPREADS ANALYSED PER DOSE (if in vitro cytogenicity study in mammalian cells): 150 cells examined
DETERMINATION OF CYTOTOXICITY
- Method: mitotic index
Microscopic Examination
The prepared slides were examined by light microscopy and the incidence of mitotic cells per 1000 cells assessed. Slides were assessed for mitotic index (except when clear evidence of overt toxicity was observed, or in cultures where there were no signs of cytotoxicity).
- Determination of polyploidy and endoreplication: he incidence of polyploid and endoreduplicated cells (i.e. the ploidy status) were each recorded as a percentage of the 150 metaphases analyzed per slide, independently from the analysis for chromosome aberrations. - Evaluation criteria:
- Acceptance Criteria:The concurrent vehicle control was considered acceptable for addition to the laboratories historical vehicle control database (lie below or close to the upper control limit). Where concurrent vehicle control data fell outside the 95% confidence limit it may be acceptable for inclusion in the historical control distribution as long as the data are not extreme outliers and there is evidence that the test system is ‘under control’ and there is evidence of no technical or human failure.Concurrent positive controls induced a response that were compatible with the laboratories historical positive control database and produced statistically significant increases compared with the concurrent vehicle control. Assessment Criteria:Providing that all of the acceptance criteria have been met, the test item was considered to be clearly positive if, in any of the experimental conditions examined: At least one of the test concentrations exhibited a statistically significant increase compared with the concurrent vehicle control.The increase was dose-related when evaluated with an appropriate trend test.Any of the results are outside the distribution of the historical vehicle control data (above the upper 95% confidence limit).If all of these criteria were met, the test item was considered able to induce chromosome breaks and/or gain or loss in the test system. Providing that all of the acceptance criteria have been met, a negative response was claimed if, in all of the experimental conditions examined: None of the test concentrations exhibited a statistically significant increase compared with the concurrent vehicle control. There was no concentration-related increase when evaluated with an appropriate trend test.All results are inside the distribution of the historical vehicle control data (within the 95% confidence limits). If all of these criteria are met, the test item was considered unable to induce chromosome breaks and/or gain or loss in the test system.
- Statistics:
- The following computerized system was used for statistical analysis: SAFEStat (SAS statistical applications for end users) Chromosome Aberrations application which was developed in SAS (SAS INSTITUTE 2002)
Results and discussion
Test results
- Key result
- Species / strain:
- lymphocytes: Human Lymphocytes
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
Applicant's summary and conclusion
- Conclusions:
- It is concluded that the test item 1132 Side Chain has shown no evidence of causing an increase in the frequency of structural chromosome aberrations in this in vitro cytogenetic test system, under the experimental conditions described.
- Executive summary:
A study was performed to assess the ability of 1132 Side Chain to cause structural chromosome aberrations in human lymphocytes cultured in vitro.
Human lymphocytes, in whole blood culture, were stimulated to divide by addition of phytohaemagglutinin (PHA), and exposed to the test item both in the absence and presence of exogenous metabolic activation (S9 mix). Vehicle and positive control cultures were also included where appropriate. Two hours before the end of the incubation period, cell division was arrested using Colcemid®, the cells harvested and slides prepared, so that metaphase cells could be examined for chromosomal damage. The study consisted of a preliminary toxicity test, a main test and an additional main test. In preliminary and main tests the cells were treated for 3 and 21 hours in the absence of S9 mix and for 3 hours in the presence of S9 mix. In the additional main test the cells were treated for 3 and 21 hours in the absence of S9 mix. The mitotic index was assessed for all cultures to determine cytotoxicity. Based on the data from the preliminary toxicity test, test item concentrations were selected for the main test.
In the main test, justification for the highest analyzed concentration was based on cytotoxicity. The following test item concentrations were selected for metaphase analysis: In the absence of S9 mix, 3-hour treatment (additional test): 20, 50 and 70 µg/mL. In the presence of S9 mix, 3-hour treatment: 20, 30 and 40 µg/mL. In the absence of S9 mix, 21-hour treatment (additional test): 10, 20 and 27.5 µg/mL. Under the conditions described above, 1132 Side Chain caused no statistically significant increases in the proportion of metaphase figures containing chromosomal aberrations (excluding gaps), at any analyzed concentration, when compared with the vehicle control. There was no evidence of a linear dose-concentration relationship. The mean proportion of cells with chromosomal aberrations (excluding gaps) for the vehicle and test item treated
cultures were within or close to the laboratory historical control range. No statistically significant increases in the proportion of polyploid or endoreduplicated metaphase cells were observed during metaphase analysis, under any treatment condition, when compared with the vehicle control. Both positive control compounds caused statistically significant increases in the proportion of aberrant cells, demonstrating the sensitivity of the test system and the efficacy of the S9 mix. It is concluded that 1132 Side Chain has shown no evidence of causing an increase in the frequency of structural chromosome aberrations in this in vitro cytogenetic test system, under the experimental conditions described.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.